We are happy to give a presentation at ESTIV congress in Barcelona (21-25 November 2022)

Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…

Collaboration between “Institut du thorax” and HCS Pharma: improving the management of hypercholesterolemia using a relevant and innovative organoid-based in vitro liver model

Launched in 2016, the adventure is coming to an end after 5 years of work carried out within the RHU CHOPIN (CHOlesterol Personalized INnovation), and with a strong collaboration between HCS Pharma and l’Institut du thorax. This collaborative project of national scope was led by Professor Bertrand Cariou, director of Read more…

Biomimesys meets Stem cells: presentations at FSSCR event and “From 3D Culture to Organoid” symposium

Biomimesys is providing a great opportunity to culture human induced pluripotent stem cells (hiPSCs) in 3D and differentiate them into different kind of cell types including liver cells. Showcased by Méryl Roudaut at the 20th International Congress on In Vitro Toxicology (ESTIV2018), our co-development with the institute du thorax (U1087) Read more…

Poster – Urine sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia

Human induced pluripotent stem cells (hiPSC) are becoming a relevant model for the study of liver metabolic diseases once differentiated into hepatocyte-like cells (HLC), and it has been shown that they can faithfully recapitulate autosomal dominant hypercholesterolemia (ADH). PCSK9 is a critical modulator of cholesterol homeostasis, and quickly became a Read more…